A Phase 2 interventional study of Plecanatide and Placebo in Irritable Bowel Syndrome Characterized by Constipation, sponsored by Bausch Health Americas, Inc.. Completed at 99 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-05-28.
Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing plecanatide in Constipation — none open to participants now, 1 under way, none of them phase 3. plecanatide · Constipation.
Among the 12 studies testing plecanatide in Constipation, this one is the 8th largest by enrollment, is the only one that started in 2012, is one of 5 in phase 2, and was the 3rd registered.
1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.
Browse Constipation studies →None of the 12 studies testing plecanatide in Constipation is open now. The open studies under Constipation, anywhere →
plecanatide: first FDA approval 2017 (TRULANCE). What it is approved for, and how studies give it, is on its page →
Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 7
First in 2010; this study’s year is marked. 1 started in 2012.
This study's enrollment of 428 is above the median of 75 across 885 interventional studies indexed under Constipation.
Median enrollment 800 across the 12 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 2 most frequent:
This study is registered under Bausch Health Americas, Inc., one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
21 studies in Constipation by Bausch Health Companies Inc.: none open now, 1 under way, none of them phase 3. Of 20 finished, 15 (75%) have results posted.
Among the 21 studies in Constipation by Bausch Health Companies Inc., this one is the 9th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2012, is one of 9 in phase 2, and was the 11th registered.
Bausch Health Companies Inc.’s Constipation studies by the year they started, since 2006.
1 of the studies testing plecanatide in Constipation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07723924Bausch Health Americas, Inc.This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC | 2027-10-18 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing plecanatide in Constipation, from their registry updates:
Among Bausch Health Companies Inc.’s 21 in Constipation:
This tab as a report to print or save as PDF → With an account.
This is a randomized, 12-week, double-blind, placebo-controlled, dose-ranging study in patients with IBS-C.
This is a randomized, 12-week, double-blind, placebo-controlled, dose-ranging study in patients with IBS-C. Patients will undergo a Screening Period to determine eligibility. After completing a Screening Visit patients will undergo a 2-week Pre-Treatment assessment using the Interactive Voice Response System (IVRS) during which they will complete daily assessments of bowel movements (BMs), stool consistency (Bristol Stool Form Scale- BSFS), abdominal pain or abdominal discomfort and other symptoms associated with IBS-C. Data from the two-week IVRS Pre-treatment assessment are used to define the patient's baseline from which change will be determined. Patients who meet all entry criteria will be randomized to one of five treatment groups ( 0.3mg,1.0mg,3.0mg,9mg,or Placebo) on Day 1 of the Treatment Period. Patients will take an oral dose of study drug daily (QD) for 12 weeks and continue the daily IVRS diaries (BMs, abdominal pain, other symptoms). On Weeks 2, 4, 8, and 12, patients will return to the clinic to undergo safety and efficacy assessments. For 2 weeks after completing dosing, (i.e., Post-Treatment Period), patients will continue to complete daily IVRS diaries. Patients will then return to the clinical site for a final follow-up visit (End of Study Visit). The planned duration of participation in this study will be approximately 112 days from signing of informed consent through post-treatment or 145 days if 30 day washout of a prohibited concomitant medication or stabilization of a medical condition is required before Pre-Treatment (up to 148 days, with all windows considered).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Plecanatide 0.3mg, one tablet by mouth daily for 12 weeks
Drug: Plecanatide
Plecanatide 1.0mg one tablet by mouth daily for 12 weeks
Drug: Plecanatide
Plecanatide 3.0mg, one tablet by mouth daily for 12 weeks
Drug: Plecanatide
Plecanatide 9.0mg, one tablet by mouth daily for 12 weeks
Drug: Plecanatide
Placebo, one tablet by mouth daily for 12 weeks
Drug: Placebo
Also known as: Trulance
Change From Baseline in Weekly CSBMs Frequency Over the 12-Week Treatment Period (mITT Population)
The primary efficacy endpoint was the change from baseline in the weekly CSBM frequency (CSBMs per week minus CSBMs per week at baseline) over a 12-week Treatment Period. A Complete Spontaneous Bowel Movement (CSBM) is a Bowel Movement (BM) that occurs in the absence of laxative use within 24 hours of the BM and the patient reports a feeling of complete evacuation.
Time frame: 12 weeks Treatment Period
Change From Baseline in Abdominal Pain Intensity Scores Over 12-Week Treatment Period (mITT Population)
Abdominal Pain was assessed in the patient's daily response on a scale of 0 to 10 where 0 is did not experience the symptom at all and 10 is experienced the worst.
Time frame: 12-Week Treatment Period
Change From Baseline in Stool Consistency (BSFS) Over 12-Week Treatment Period (mITT Population)
The stool consistency of each bowel movement (BM) was assessed by patients using the 7-point Bristol Stool Form Scale \[BSFS\] from 1 to 7. 1. = separate hard lumps like nuts (difficult to pass) 2. = sausage shaped but lumpy 3. = like a sausage but with cracks on its surface 4. = like a sausage or snake, smooth and soft 5. = soft blobs with clear-cut edges (passed easily) 6. = fluffy pieces with ragged edges, a mushy stool 7. = watery, no solid pieces (entirely liquid)
Time frame: 12-Week Treatment Period
Change From Baseline in Straining Scores Over 12-Week Treatment Period (mITT Population)
The severity of straining (Straining Score) was rated by the patients using a 11-point scale (0-10) where 0 = none and 10 = very severe
Time frame: 12-Week Treatment Period
| Milestone | Plecanatide 0.3mg | Plecanatide 1.0mg | Plecanatide 3.0mg | Plecanatide 9.0mg | Placebo |
|---|---|---|---|---|---|
| Started | 86 | 85 | 86 | 85 | 86 |
| Completed | 72 | 65 | 66 | 65 | 68 |
| Not completed | 14 | 20 | 20 | 20 | 18 |
The primary efficacy endpoint was the change from baseline in the weekly CSBM frequency (CSBMs per week minus CSBMs per week at baseline) over a 12-week Treatment Period. A Complete Spontaneous Bowel Movement (CSBM) is a Bowel Movement (BM) that occurs in the absence of laxative use within 24 hours of the BM and the patient reports a feeling of complete evacuation.
| CSBMs per week | Plecanatide 0.3mg | Plecanatide 1.0mg | Plecanatide 3.0mg | Plecanatide 9.0mg | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Weekly CSBMs Frequency Over the 12-Week Treatment Period (mITT Population) | 1.28 ± 0.260 | 2.12 ± 0.265 | 2.74 ± 0.260 | 2.44 ± 0.262 | 1.27 ± 0.260 |
Abdominal Pain was assessed in the patient's daily response on a scale of 0 to 10 where 0 is did not experience the symptom at all and 10 is experienced the worst.
| scores on a scale | Plecanatide 0.3mg | Plecanatide 1.0mg | Plecanatide 3.0mg | Plecanatide 9.0mg | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Abdominal Pain Intensity Scores Over 12-Week Treatment Period (mITT Population) | -1.5 ± 0.20 | -1.5 ± 0.20 | -2.0 ± 0.20 | -1.8 ± 0.20 | -1.4 ± 0.20 |
The stool consistency of each bowel movement (BM) was assessed by patients using the 7-point Bristol Stool Form Scale \[BSFS\] from 1 to 7. 1. = separate hard lumps like nuts (difficult to pass) 2. = sausage shaped but lumpy 3. = like a sausage but with cracks on its surface 4. = like a sausage or snake, smooth and soft 5. = soft blobs with clear-cut edges (passed easily) 6. = fluffy pieces with ragged edges, a mushy stool 7. = watery, no solid pieces (entirely liquid)
| scores on a scale | Plecanatide 0.3mg | Plecanatide 1.0mg | Plecanatide 3.0mg | Plecanatide 9.0mg | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Stool Consistency (BSFS) Over 12-Week Treatment Period (mITT Population) | 1.63 ± 0.143 | 1.81 ± 0.144 | 2.49 ± 0.143 | 2.24 ± 0.145 | 1.01 ± 0.143 |
The severity of straining (Straining Score) was rated by the patients using a 11-point scale (0-10) where 0 = none and 10 = very severe
| score on a scale | Plecanatide 0.3mg | Plecanatide 1.0mg | Plecanatide 3.0mg | Plecanatide 9.0mg | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Straining Scores Over 12-Week Treatment Period (mITT Population) | -1.7 ± 0.23 | -1.5 ± 0.23 | -2.2 ± 0.23 | -2.1 ± 0.24 | -1.3 ± 0.23 |
Collected over 12 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Plecanatide 0.3mg | — | 1/85 (1.2%) | 18/85 (21.2%) |
| Plecanatide 1.0mg | — | 0/85 (0%) | 29/85 (34.1%) |
| Plecanatide 3.0mg | — | 1/86 (1.2%) | 19/86 (22.1%) |
| Plecanatide 9.0mg | — | 2/85 (2.4%) | 31/85 (36.5%) |
| Placebo | — | 0/86 (0%) | 12/86 (14%) |
| Event | Plecanatide 0.3mg | Plecanatide 1.0mg | Plecanatide 3.0mg | Plecanatide 9.0mg | Placebo |
|---|---|---|---|---|---|
| AppendicitisInfections and infestations | 1/85 | 0/85 | 0/86 | 0/85 | 0/86 |
| Bile duct stoneHepatobiliary disorders | 0/85 | 0/85 | 0/86 | 1/85 | 0/86 |
| Supraventricular tachycardiaCardiac disorders | 0/85 | 0/85 | 0/86 | 1/85 | 0/86 |
| Cholecystitis acuteHepatobiliary disorders | 0/85 | 0/85 | 1/86 | 0/85 | 0/86 |
| Event | Plecanatide 0.3mg | Plecanatide 1.0mg | Plecanatide 3.0mg | Plecanatide 9.0mg | Placebo |
|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/85 | 8/85 | 8/86 | 10/85 | 0/86 |
| HeadacheNervous system disorders | 2/85 | 5/85 | 3/86 | 8/85 | 4/86 |
| Urinary tract infectionInfections and infestations | 1/85 | 5/85 | 3/86 | 1/85 | 1/86 |
| NauseaGastrointestinal disorders | 4/85 | 1/85 | 2/86 | 4/85 | 5/86 |
| Back painMusculoskeletal and connective tissue disorders | 1/85 | 4/85 | 0/86 | 2/85 | 0/86 |
| Oropharyngeal PainRespiratory, thoracic and mediastinal disorders | 3/85 | 3/85 | 0/86 | 1/85 | 1/86 |
| Upper Respiratory Tract InfectionInfections and infestations | 2/85 | 2/85 | 1/86 | 3/85 | 1/86 |
| FatigueGeneral disorders | 2/85 | 1/85 | 2/86 | 2/85 | 0/86 |
The Randomized Population (428 patients) in Participant Flow differs from the mITT Population (423 patients) because 1 patient was randomized and not dosed, 1 patient was dosed but had no post-baseline efficacy assessments, and 3 duplicate patient records (2 patients who were seen at 2 sites and 1 patient who was seen at 3 sites)
| Age, Continuous(years) | Plecanatide 0.3mg | Plecanatide 1.0mg | Plecanatide 3.0mg | Plecanatide 9.0mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 47.2 ± 12.02 | 44.6 ± 12.58 | 47.2 ± 12.89 | 45.3 ± 12.00 | 45.4 ± 12.02 | 45.9 ± 12.30 |
| Sex: Female, Male(Participants) | Plecanatide 0.3mg | Plecanatide 1.0mg | Plecanatide 3.0mg | Plecanatide 9.0mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 68 | 67 | 70 | 70 | 69 | 344 |
| Male | 16 | 16 | 16 | 15 | 16 | 79 |
The record gives a start of Nov 2012, a primary completion of Apr 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2018, 4 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Plecanatide
Bausch Health Americas, Inc. →